The European Commission announced Tuesday it signed a joint procurement contract with HIPRA for the supply of its protein-based COVID-19 vaccine amid the increasing number of coronavirus cases in Europe.
Under the joint procurement, 14 member states will be able to buy up to 250 million doses. After being approved by HERA, the European Commission's Health Preparedness and Response Authority, the HIPRA vaccine is currently under rolling review by the European Medicines Agency.
"With COVID-19 infections on the rise in Europe, we need to ensure maximum preparedness as we head into the autumn and winter month," said Commissioner for Health and Food Safety Stella Kyriakides."The HIPRA vaccine adds yet another option to complement our broad vaccine portfolio for our Member States and citizens."
